Christy Jones Sells 2,811 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 2,811 shares of Beta Bionics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $14.00, for a total transaction of $39,354.00. Following the transaction, the director owned 27,400 shares in the company, valued at $383,600. This represents a 9.30% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christy Jones also recently made the following trade(s):

• On Thursday, May 21st, Christy Jones sold 1,998 shares of Beta Bionics stock. The shares were sold at an average price of $9.95, for a total transaction of $19,880.10.

Beta Bionics Price Performance

Shares of BBNX stock opened at $13.89 on Friday. The company has a market capitalization of $618.94 million, a price-to-earnings ratio of -9.20 and a beta of 3.40. Beta Bionics, Inc. has a one year low of $8.80 and a one year high of $32.71. The company’s fifty day moving average price is $10.93 and its 200-day moving average price is $17.19.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. The firm had revenue of $27.63 million for the quarter. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. Equities research analysts expect that Beta Bionics, Inc. will post -2.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BBNX has been the topic of a number of research reports. Leerink Partners dropped their price objective on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. Truist Financial dropped their price target on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. Finally, Stifel Nicolaus reduced their price target on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.70.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BBNX. Strs Ohio purchased a new stake in shares of Beta Bionics in the 1st quarter valued at $29,000. EverSource Wealth Advisors LLC raised its position in Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after acquiring an additional 1,594 shares during the period. Summit Securities Group LLC acquired a new position in Beta Bionics during the fourth quarter worth $52,000. Legal & General Group Plc raised its position in Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after acquiring an additional 2,639 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after buying an additional 1,818 shares during the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.